Please login to the form below
Tonix appoints head of clinical development
Donald Kellerman has experience at Allergan, Map, Inspire and Glaxo Wellcome
Tonix Pharmaceuticals has appointed Dr Donald Kellerman to head the strategy and execution of its clinical programmes.
Dr Kellerman brings 30 years of industry experience to his new role as senior VP, clinical development and regulatory affairs.
This includes his most recent role as VP, scientific affairs for Allergan's inhalation products business. He took on this role after his previous company, Map Pharmaceuticals, was taken over by Allergan in 2013.
At Map, Dr Kellerman served as senior VP, clinical development and medical affairs at Map Pharmaceuticals having joined the company in 2008 from Inspire Pharmaceuticals.
He also has experience at GlaxoWellcome as director of respiratory clinical research.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
